Kaia Health has just announced a $75 million funding round for its technology, aimed at improving musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD) care.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
